VivoSim Labs, INC. (VIVS) Financial Statements
Industry: Biological Products, (No Diagnostic Substances)
In fiscal 2026, VivoSim Labs reported revenue of $131,000, down 9.0% from $144,000 the year before. Net income was -$13.8M (a -10567.2% net margin), or -$5.35 per diluted share. Gross margin was 100.0% and operating margin was -8768.7%. Operating activities generated -$10.8M of cash, leaving -$10.8M of free cash flow. At fiscal year end, VivoSim Labs held $7.4M in total assets against $8.5M in total liabilities, including $5.0M of cash and equivalents.
Open the full interactive VivoSim Labs financials → Quarterly statements, key ratios, valuation history and price charts.
VivoSim Labs Key Stats
| Share Price | $0.17 |
|---|---|
| Market Cap | $890,709 |
| Revenue YoY Growth | -9.0% |
| 52-Week Range | $0.17 – $2.98 |
| Shares Outstanding | 5.2 million (basic, 2027 Q1) |
VivoSim Labs Income Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $1.5M | $370,000 | $109,000 | $144,000 | $131,000 |
| Cost of Goods Sold | $0 | — | — | — | $5,000 | $0 |
| Gross Profit | $0 | — | — | — | $139,000 | $131,000 |
| Operating Income | -$16.8M | -$11.5M | -$17.7M | -$15.1M | -$12.6M | -$11.5M |
| Pre-Tax Income | -$16.8M | -$11.4M | -$17.3M | -$14.7M | -$12.6M | -$13.8M |
| Income Tax | $2,000 | $2,000 | $2,000 | $2,000 | $2,000 | $2,000 |
| Net Income | -$16.8M | -$11.4M | -$17.3M | -$14.7M | -$2.5M | -$13.8M |
| Diluted EPS | -$29.28 | -$15.84 | -$23.76 | -$19.20 | -$1.70 | -$5.35 |
VivoSim Labs Quarterly Results
| 2026 Q2 | 2026 Q3 | 2026 Q4 | 2027 Q1 | |
|---|---|---|---|---|
| Revenue | $28,000 | $26,000 | $40,000 | $18,000 |
| Net Income | -$2.5M | -$2.7M | -$5.8M | -$1.3M |
| Diluted EPS | -$0.98 | -$1.03 | -$2.23 | -$0.25 |
VivoSim Labs Balance Sheet
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $37.4M | $28.7M | $15.3M | $2.9M | $11.3M | $5.0M |
| Current Assets | $38.4M | $29.5M | $17.0M | $3.9M | $12.1M | $6.6M |
| Total Assets | $39.9M | $33.3M | $20.3M | $6.3M | $14.7M | $7.4M |
| Current Liabilities | $721,000 | $1.4M | $3.7M | $1.9M | $3.7M | $2.8M |
| Total Liabilities | $721,000 | $3.1M | $5.0M | $2.7M | $4.2M | $8.5M |
| Shareholders' Equity | $39.2M | $30.2M | $15.3M | $3.6M | $10.5M | -$1.1M |
VivoSim Labs Cash Flow Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$13.3M | -$8.5M | -$12.4M | -$14.7M | -$9.5M | -$10.8M |
| Cash From Investing | -$393,000 | -$409,000 | -$966,000 | $816,000 | $9.0M | $94,000 |
| Cash From Financing | $23.8M | $205,000 | $0 | $1.4M | $8.8M | $4.4M |
| Free Cash Flow | -$13.7M | -$8.9M | -$12.8M | -$14.7M | -$9.5M | -$10.8M |
Figures from VivoSim Labs' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full VivoSim Labs financials page for every line item.
VivoSim Labs Company Profile
| Ticker | VIVS |
|---|---|
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Headquarters | San Diego, California |
| Incorporated in | Delaware |
| Fiscal Year End | March 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001497253 |
Frequently Asked Questions
What was VivoSim Labs' revenue in fiscal 2026?
VivoSim Labs (VIVS) reported revenue of $131,000 for fiscal 2026.
What is VivoSim Labs' annual revenue history?
VivoSim Labs' annual revenue by fiscal year: 2021: $0; 2022: $1.5M; 2023: $370,000; 2024: $109,000; 2025: $144,000; 2026: $131,000.
What was VivoSim Labs' net income in fiscal 2026?
VivoSim Labs reported net income of -$13.8M for fiscal 2026.
What was VivoSim Labs' earnings per share (EPS) in fiscal 2026?
VivoSim Labs' diluted EPS was -$5.35 for fiscal 2026 (adjusted for any later stock splits).
How much free cash flow did VivoSim Labs generate in fiscal 2026?
VivoSim Labs generated -$10.8M of free cash flow in fiscal 2026.
What was VivoSim Labs' revenue last quarter?
In its most recent reported quarter (2027 Q1), VivoSim Labs reported revenue of $18,000.
How many shares of VivoSim Labs are outstanding?
VivoSim Labs reported a weighted average of 5.2 million basic shares outstanding in 2027 Q1.
What is VivoSim Labs' market cap?
Based on its latest closing price, VivoSim Labs (VIVS) has a market capitalization of about $890,709.
When does VivoSim Labs' fiscal year end?
VivoSim Labs' fiscal year end, as registered with the SEC, is March 31.
Where is VivoSim Labs headquartered?
VivoSim Labs lists its business address in San Diego, California in its SEC filings.
VivoSim Labs Competitors & Similar Companies
See all 136 Biological Products, (No Diagnostic Substances) companies →